List of Vaccines Companies in Oregon - 3

Najít Technologies is dedicated to the development of safe and effective vaccines against infectious diseases of global importance.

PDX Pharmaceuticals is an IND-enabling stage biopharmaceutical company. We develop novel combination and immunotherapies to treat cancer by bringing complementary biological pathways together to achieve synergistic clinical benefit. Our therapeutic candidates bridge the innate and adaptive immune systems by generating profound CD8+ T cell production. Our pipelines are patented AIRISE (Augmenting Immune Responses and Inhibiting the Suppressive Environment of Tumors) and ARAC (Antigen Release Agent and Checkpoint Inhibitor) pipelines that generate anti-tumor immunity when given locally (AIRISE) or systemically (ARAC) by relying on patient' s own tumor in situ as the source of antigens.

UbiVac is a clinical stage biotech engaged in research and development, and manufacture, of therapeutic immune activators, vaccines and cellular immunotherapies to combat cancer. Used in combination with other immunotherapies, UbiVac’s patented technologies have proven highly effective at improving survival and apparent cure in difficult to treat animal cancers (PMID: 27874054; PMID: 31747946; PMID: 22068657). UbiVac believes that the explanation for this effectiveness lies in several high impact publications from 2021 identifying a previously unknown class of shared non-mutated cancer neoantigens that make up as much as 25% of the antigens on cancer cells (PMID: 33740418; PMID: 33691108; PMID: 34663921). As the non-mutated shared cancer neoantigens are short-lived proteins, the majority are expected to be contained in UbiVac’s DPV-001. Importantly, these findings help explain why UbiVac’s immunotherapy provided cross-protective cancer immunity in preclinical models, something that had not been observed in 50 years of study (PMID: 21810919). These remarkable studies raised the possibility of off-the-shelf Universal Cancer Vaccines (PMID: 33852826). UbiVac has completed an NCI-funded phase I/II adjuvant trial of its lead agent, DPV-001. This trial met its endpoints, determined safety, identified drug formulation, and demonstrated proof-of-concept. Based on these data UbiVac partnered with the Providence Cancer Institute and Incyte on a first-in-human immunotherapy trial of UbiVac’s DPV-001, anti-GITR and anti-PD-1 for advanced HNSCC. The first patients were treated in Q4 2021, and preliminary immunological monitoring data will be presented at AACR in April 2022. UbiVac also has a pipeline of cellular therapies under development. Given that UbiVac’s CEO and CSO, together, have 55+ years of experience with preclinical and clinical studies of adoptive immunotherapy, UbiVac is well positioned to bring their innovative cellular therapy platforms to the clinic.